시장보고서
상품코드
1485047

반려동물 의약품 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측, 적응증별, 동물별, 유통 채널별, 지역별, 경쟁사별(2019-2029년)

Companion Animal Pharmaceuticals Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Indication, By Animal, By Distribution Channel, By Region and Competition, 2019-2029F

발행일: | 리서치사: TechSci Research | 페이지 정보: 영문 180 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    


■ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

반려동물 의약품 세계 시장 규모는 2023년 145억 2,000만 달러로 평가되었고, 2029년까지 8.25%의 연평균 복합 성장률(CAGR)을 나타내며 예측 기간 동안 꾸준히 성장할 것으로 예상됩니다.

세계 반려동물 의약품 시장은 반려동물 사육 인구 증가, 반려동물 건강에 대한 인식 증가, 수의학 발전 등 다양한 요인이 겹치면서 최근 몇 년동안 큰 폭으로 성장하고 있습니다. 개, 고양이, 말 등 반려동물은 전 세계 수백만 명의 삶에 필수적인 역할을 하고 있으며, 이는 반려동물의 건강상 필요에 맞는 의약품에 대한 수요 증가로 이어지고 있습니다. 시장 성장의 주요 촉진요인 중 하나는 반려동물이 가족의 소중한 일원으로 인식되면서 반려동물의 인간화가 진행되고 있다는 점입니다. 이러한 인식의 변화로 인해 반려동물 보호자들은 반려동물의 건강을 보장하기 위한 예방적 건강관리 대책과 치료에 대한 투자 의지가 높아지고 있습니다. 그 결과, 벼룩과 진드기 치료제부터 관절염, 당뇨병과 같은 만성질환 치료제까지 반려동물 의약품에 대한 수요가 급증하고 있습니다. 수의학의 발전과 혁신적인 의약품의 가용성은 반려동물에게 제공되는 치료 옵션을 확대했습니다. 수의사들은 현재 반려동물의 일반적인 질병부터 복잡한 질환에 이르기까지 다양한 건강 문제를 해결하기 위해 다양한 의약품과 치료법을 이용할 수 있습니다. 또한, 경피 패치 및 향료 의약품과 같은 새로운 약물 전달 시스템의 개발로 반려동물 보호자가 반려동물에게 약물을 쉽게 투여할 수 있게 되어 순응도와 치료 결과가 향상되었습니다.

시장 개요
예측 기간 2025-2029년
시장 규모 : 2023년 145억 2,000만 달러
시장 규모 : 2029년 232억 7,000만 달러
CAGR : 2024-2029년 8.25%
급성장 부문 피부질환
최대 시장 북미

반려동물의 질병과 장애의 유병률이 증가함에 따라 제약 솔루션에 대한 수요가 증가하고 있습니다. 비만, 알레르기, 치아 문제 등의 증상이 반려동물에게 점점 더 흔해지면서 효과적인 약물과 치료법의 필요성이 높아지고 있습니다. 또한, 수의학적 치료와 영양 개선으로 반려동물의 수명이 길어짐에 따라 관절염, 인지기능 장애와 같은 노화 관련 질환의 발생률이 증가하면서 반려동물 의약품에 대한 수요가 더욱 증가하고 있습니다. 지리적으로 북미는 높은 반려동물 사육률, 선진화된 수의학 의료 인프라, 강력한 규제 체계로 인해 세계 반려동물 의약품 시장을 주도하고 있습니다. 유럽과 아시아태평양도 반려동물 보유율 증가, 가처분 소득 증가, 반려동물의 건강 및 웰빙에 대한 인식 증가로 인해 큰 시장 점유율을 차지하고 있습니다.

유망한 성장 전망에도 불구하고 반려동물 의약품 시장은 몇 가지 문제에 직면해 있습니다. 여기에는 의약품 승인 과정과 관련된 규제적 장애물, 가격 압력, 허브 보충제 및 전체론적 치료와 같은 대체 요법과의 경쟁 등이 포함됩니다. 또한, 현재 진행 중인 코로나19 팬데믹은 시장 역학에 영향을 미치고 있으며, 공급망 혼란과 소비자 행동의 변화를 초래하고 있습니다.

세계 반려동물 의약품 시장 전망은 동물 의료의 지속적인 발전, 반려동물의 인간화 추세, 전 세계 반려동물 양육률 증가에 힘입어 계속해서 밝게 전망되고 있습니다. 반려동물 보호자들이 반려동물의 건강과 행복을 우선시하는 경향이 지속됨에 따라 혁신적인 의약품과 치료법에 대한 수요가 증가할 것으로 예상됩니다. 제약사, 수의사, 연구기관의 협력은 시장의 혁신과 확장을 촉진하고 궁극적으로 전 세계 반려동물과 보호자에게 혜택을 줄 수 있을 것으로 보입니다.

주요 시장 성장 촉진요인

반려동물 사육률 상승

가처분소득 증가

주요 시장 과제

규제상의 장애물

위조품

주요 시장 동향

기술의 발전

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 세계의 반려동물 의약품 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 적응증별(감염증, 피부질환, 통증, 정형외과 질환, 행동 질환, 기타)
    • 동물별(개, 고양이, 말, 기타)
    • 유통 채널별(동물 병원 및 진료소, 약국 소매, 기타)
    • 지역별
    • 기업별(2023년)
  • 시장 맵
    • 적응증별
    • 동물별
    • 유통 채널별
    • 지역별

제5장 아시아태평양의 반려동물 의약품 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 적응증별
    • 동물별
    • 유통 채널별
    • 국가별
  • 아시아태평양 : 국가별 분석
    • 중국
    • 인도
    • 호주
    • 일본
    • 한국

제6장 유럽의 반려동물 의약품 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 적응증별
    • 동물별
    • 유통 채널별
    • 국가별
  • 유럽 : 국가별 분석
    • 프랑스
    • 독일
    • 스페인
    • 이탈리아
    • 영국

제7장 북미의 반려동물 의약품 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 적응증별
    • 동물별
    • 유통 채널별
    • 국가별
  • 북미 : 국가별 분석
    • 미국
    • 멕시코
    • 캐나다

제8장 남미의 반려동물 의약품 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 적응증별
    • 동물별
    • 유통 채널별
    • 국가별
  • 남미 : 국가별 분석
    • 브라질
    • 아르헨티나
    • 콜롬비아

제9장 중동 및 아프리카의 반려동물 의약품 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 적응증별
    • 동물별
    • 유통 채널별
    • 국가별
  • 중동 및 아프리카 : 국가별 분석
    • 남아프리카공화국
    • 사우디아라비아
    • 아랍에미리트(UAE)

제10장 시장 역학

  • 성장 촉진요인
  • 과제

제11장 시장 동향과 발전

  • 최근 동향
  • 제품 출시
  • 인수합병(M&A)

제12장 세계의 반려동물 의약품 시장 : SWOT 분석

제13장 Porter의 Five Forces 분석

  • 업계내 경쟁
  • 신규 참여 가능성
  • 공급업체의 힘
  • 고객의 힘
  • 대체품의 위협

제14장 경쟁 구도

  • Zoetis Services LLC
  • Merck & Co., Inc.
  • Boehringer Ingelheim International GmbH
  • Elanco Animal Health Incorporated
  • Virbac Taiwan Co., Ltd.
  • Vetoquinol S.A.
  • Dechra Pharmaceuticals Limited
  • Chanelle Pharma
  • KyoritsuSeiyaku Corp

제15장 전략적 제안

제16장 리서치사에 대해 & 면책사항

LSH 24.06.04

Global Companion Animal Pharmaceuticals Market was valued at USD 14.52 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 8.25% through 2029. The global companion animal pharmaceuticals market has witnessed significant growth in recent years, driven by a combination of factors including increasing pet ownership, rising awareness about pet health, and advancements in veterinary medicine. Companion animals, including dogs, cats, and horses, play an integral role in the lives of millions of people worldwide, leading to a growing demand for pharmaceutical products tailored to their specific health needs. One of the key drivers of market growth is the increasing pet humanization trend, where pets are considered valued members of the family. This shift in perception has led to a greater willingness among pet owners to invest in preventive healthcare measures and treatments to ensure the well-being of their furry companions. As a result, there has been a surge in the demand for companion animal pharmaceuticals, ranging from flea and tick treatments to medications for chronic conditions like arthritis and diabetes. Advancements in veterinary medicine and the availability of innovative pharmaceutical formulations have expanded the treatment options available for companion animals. Veterinarians now have access to a wide array of drugs and therapies to address various health issues in pets, ranging from common ailments to complex medical conditions. Additionally, the development of novel drug delivery systems, such as transdermal patches and flavored medications, has made it easier for pet owners to administer medications to their animals, improving compliance and treatment outcomes.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 14.52 Billion
Market Size 2029USD 23.27 Billion
CAGR 2024-20298.25%
Fastest Growing SegmentDermatologic Diseases
Largest MarketNorth America

The increasing prevalence of diseases and disorders in companion animals has fueled the demand for pharmaceutical solutions. Conditions such as obesity, allergies, and dental problems are becoming more prevalent among pets, driving the need for effective medications and therapies. Additionally, as pets live longer due to improved veterinary care and nutrition, there is a growing incidence of age-related ailments such as arthritis and cognitive dysfunction, further driving the demand for companion animal pharmaceuticals. Geographically, North America dominates the global companion animal pharmaceuticals market, attributed to the high pet ownership rates, advanced veterinary healthcare infrastructure, and strong regulatory framework. Europe and Asia-Pacific also hold significant market shares, driven by increasing pet adoption rates, rising disposable incomes, and growing awareness about pet health and wellness.

Despite the promising growth prospects, the companion animal pharmaceuticals market faces certain challenges. These include regulatory hurdles associated with drug approval processes, pricing pressures, and competition from alternative therapies such as herbal supplements and holistic treatments. Additionally, the ongoing COVID-19 pandemic has impacted the market dynamics, leading to disruptions in supply chains and changes in consumer behavior.

The outlook for the global companion animal pharmaceuticals market remains positive, fueled by continued advancements in veterinary medicine, growing pet humanization trends, and increasing pet ownership rates globally. As pet owners continue to prioritize the health and well-being of their furry companions, the demand for innovative pharmaceutical products and treatments is expected to rise. Collaborations between pharmaceutical companies, veterinarians, and research institutions are likely to drive further innovation and expansion in the market, ultimately benefiting companion animals and their owners worldwide.

Key Market Drivers

Rising Pet Ownership

The global companion animal pharmaceuticals market has experienced significant growth, with a primary driving force being the increasing number of pets worldwide. As people's love and attachment to their furry and feathered friends continue to grow, the demand for products and medications designed to enhance the health and well-being of companion animals has surged. This trend not only benefits pets and their owners but also presents a wealth of opportunities for pharmaceutical companies and the broader veterinary industry. Pet ownership has become more popular than ever, with pets increasingly viewed as cherished members of the family. This shift in perspective has led to greater investments in the health and well-being of companion animals. As people's lifestyles become busier, many are turning to pets for companionship and emotional support, especially in urban areas where social connections may be limited. The increasing recognition of the positive impact pets can have on human mental health has driven more individuals to adopt pets, leading to an expansion of the pet market. Society's changing attitudes have led to a reduction in the stigma associated with renting or living in smaller spaces with pets, making pet ownership more feasible for a wider range of people. Rising income levels in many parts of the world have allowed individuals to allocate more resources to their pets, including pharmaceutical products and healthcare.

The flourishing pet ownership trend has led to a surge in demand for companion animal pharmaceuticals, creating a flourishing global market. These pharmaceuticals encompass a wide range of products, including medications, vaccines, supplements, and various healthcare products tailored for pets. Pet owners are increasingly proactive in safeguarding their pets' health. Regular veterinary check-ups, vaccinations, and preventive treatments are becoming the norm, leading to greater pharmaceutical sales. The growing elderly pet population means an increased need for medications to manage age-related conditions, such as arthritis, diabetes, and heart disease. This trend has created opportunities for pharmaceutical companies to develop and market specialized medications. The development of medications and treatments specifically formulated for companion animals has become a significant driver of the market. These tailored solutions cater to the unique needs and preferences of pet owners. Companion animal pharmaceutical companies are constantly innovating, offering an ever-expanding range of products, from oral medications and topical treatments to advanced surgeries and specialty diets. Pet owners are investing more in veterinary services, which often involve the prescription and administration of pharmaceuticals. This trend fosters a symbiotic relationship between the veterinary industry and the pharmaceutical sector.

Increasing Disposable Income

The global companion animal pharmaceuticals market is experiencing a significant surge in growth, and one of the primary factors fueling this expansion is the increasing disposable income of pet owners. In recent years, pets have become more than just loyal companions; they are now considered part of the family. This shift in perspective has led to a substantial increase in pet healthcare spending, driving the companion animal pharmaceuticals market to new heights. In today's world, pets are treated as family members, receiving the same love and care that humans do. This shift in attitude, often referred to as the humanization of pets, has led to an upsurge in spending on pet healthcare. Pet owners are more willing to invest in the health and well-being of their furry friends, leading to a boom in the global companion animal pharmaceuticals market.

The primary driver behind the companion animal pharmaceuticals market's growth is the rise in disposable income of pet owners. With higher disposable incomes, individuals are more inclined to provide their pets with better healthcare, nutrition, and overall well-being. This upward trend is observed not only in developed countries but also in emerging markets, where disposable income is steadily on the rise. With increasing disposable income, pet owners can afford advanced healthcare services and treatments for their animals. This includes regular veterinary check-ups, vaccinations, and preventive care. As a result, pharmaceutical companies have witnessed a surge in the demand for companion animal pharmaceuticals to cater to these growing healthcare needs. Pet owners are now opting for premium and specialized pharmaceutical products to address specific health issues their animals may face. This includes medications, supplements, and even therapeutic diets. The increasing disposable income allows pet owners to invest in these high-quality products to ensure their pets' health and happiness. Higher disposable income has also enabled pet owners to become more aware and educated about their animals' health needs. They are willing to invest in knowledge, ensuring that they make informed decisions about their pets' healthcare. As a result, the demand for pharmaceuticals and healthcare products has surged.

Key Market Challenges

Regulatory Hurdles

One of the significant challenges for the companion animal pharmaceuticals market is the complex and evolving regulatory landscape. The industry must navigate through a multitude of regulations and guidelines that vary from one country to another. Different regulatory bodies in different regions may require varying levels of testing, safety assessments, and approvals for pet medications and vaccines. This can make it difficult for companies to efficiently develop and market products on a global scale. As the demand for companion animal pharmaceuticals continues to grow, the market has become increasingly competitive. Numerous companies are entering the market, leading to a broader range of products and services. While this competition can be beneficial for consumers and the overall industry, it can pose challenges for established companies seeking to maintain market share and profitability.

Counterfeit Products

The global companion animal pharmaceuticals market is plagued by the issue of counterfeit products. Counterfeit medications and vaccines can be harmful to pets and undermine trust in the industry. Consumers need to be vigilant and purchase products from reputable sources. Manufacturers and regulatory authorities must work together to combat the production and distribution of counterfeit pharmaceuticals. While awareness of the importance of pet healthcare has increased, there is still room for improvement. Many pet owners may not fully understand the need for regular veterinary visits, vaccinations, and the use of pharmaceuticals. This lack of awareness can limit the market's growth potential, as pet owners may not seek preventive healthcare for their animals until health issues become severe.

Ethical concerns regarding the testing of pharmaceutical products on animals can be a significant challenge in the industry. Many consumers and animal welfare organizations demand more ethical and humane approaches to testing. Companies must invest in alternative testing methods and clearly communicate their commitment to animal welfare to maintain public trust. The global supply chain, like many industries, has faced disruptions in recent times, with events like the COVID-19 pandemic affecting the production and distribution of pharmaceuticals. Supply chain disruptions can lead to product shortages, delayed deliveries, and increased costs. Companies in the companion animal pharmaceuticals market must have resilient supply chain strategies in place to mitigate these challenges.

Key Market Trends

Technological Advancements

The global companion animal pharmaceuticals market has experienced significant growth over the years, and one of the key drivers behind this expansion is the continuous wave of technological advancements. As technology evolves, it enhances the research, development, and delivery of innovative pharmaceutical solutions for our beloved pets. Technological advancements in genomics and biotechnology have revolutionized the development of companion animal pharmaceuticals. Researchers can now better understand the genetic makeup of animals, allowing for the creation of personalized medicines tailored to an individual pet's needs. This level of precision ensures safer and more effective treatments.

The integration of telemedicine and telehealth platforms has allowed pet owners to access veterinary consultations and prescription medications more conveniently. With the help of remote monitoring, digital health records, and telepharmacy services, pet owners can receive expert advice and order medications online, reducing the need for physical visits to the vet. Advancements in drug delivery systems have made administering medications to pets easier and more effective. Innovative methods such as transdermal patches, oral syrups, and extended-release formulations improve pet owners' ability to ensure their animals receive the right dose of medication at the right time. The use of big data analytics and artificial intelligence has enabled pharmaceutical companies and veterinarians to analyze vast amounts of data to improve treatment outcomes. AI can help in diagnosing diseases, predicting treatment responses, and identifying potential side effects, leading to more precise treatment options.

Continuous technological advancements provide opportunities for pharmaceutical companies to develop novel therapies and medications for companion animals. This, in turn, allows veterinarians to provide a higher standard of care for their patients. With the rise of online platforms and e-commerce, pharmaceutical companies can reach a broader customer base. Pet owners can easily order medications and pet health products, increasing convenience and accessibility. As technology bridges global divides, pharmaceutical companies have the chance to expand their reach beyond domestic markets. The global companion animal pharmaceuticals market presents immense growth potential for companies willing to enter new regions. Technological advancements often require collaboration between pharmaceutical companies, veterinary practices, and technology providers. These partnerships can lead to the development of innovative solutions and improve the overall ecosystem of companion animal healthcare.

Segmental Insights

Indication Insights

Based on indication, dermatologic diseases emerged as the fastest growing segment in the global market for companion animal pharmaceuticals in 2023. Dermatologic diseases encompass a wide range of conditions that affect the skin, hair, and nails of companion animals. These conditions can be caused by a variety of factors, including allergies, infections, parasites, autoimmune disorders, and more. Dermatologic issues are common in both dogs and cats, and they often manifest as itching, rashes, hair loss, and skin infections. These ailments can significantly reduce the quality of life for pets and can be distressing for their owners.

The high prevalence of dermatologic diseases in companion animals has led to an increased demand for pharmaceutical products specifically designed to treat these conditions. This demand has a significant impact on the global companion animal pharmaceuticals market in several ways. To meet the needs of pet owners, pharmaceutical companies have been investing in research and development to create more effective and convenient treatments for dermatologic diseases. These innovations include new topical creams, shampoos, oral medications, and injections, allowing veterinarians and pet owners a broader array of options for managing these conditions. The rising incidence of dermatologic diseases has prompted pharmaceutical companies to expand their product lines. This means a greater variety of treatment options are now available, catering to different types of skin issues, severity levels, and pet preferences. Dermatologic conditions often require professional diagnosis and management. This has led to an increase in demand for veterinary services specializing in dermatology, further driving the need for pharmaceutical products. These specialists can provide tailored treatment plans and recommendations for companion animals with skin issues.

Animal Insights

Based on animal, dogs segment is projected to experience rapid growth in Global Companion Animal Pharmaceuticals Market during the forecast period. The global pet population is on the rise, with dogs being one of the most popular choices as companions. The emotional bond between humans and their dogs has driven pet owners to prioritize the health and well-being of their four-legged family members. As a result, there is a growing demand for pharmaceutical products and services tailored to dogs' unique healthcare needs. With advancements in veterinary medicine and nutrition, dogs are living longer, healthier lives. However, like humans, older dogs are prone to various health issues, such as arthritis, diabetes, and cardiovascular problems. This aging demographic of dogs has led to an increased need for specialized pharmaceuticals to address age-related ailments, ultimately contributing to the growth of the companion animal pharmaceuticals market.

The concept of preventive healthcare for pets has gained momentum in recent years. Dog owners are increasingly focused on keeping their pets healthy and preventing diseases rather than just treating them when they occur. This trend has led to the expansion of product lines that include vaccines, flea and tick preventatives, and nutritional supplements, all of which boost the companion animal pharmaceuticals market. As dogs continue to be considered integral members of the family, there has been a rise in the humanization of pets. Dog owners are more willing to invest in their pets' well-being, which includes spending on higher-quality foods, pharmaceuticals, and veterinary services. This shift in perspective has led to increased expenditures on companion animal pharmaceuticals.

Regional Insights

Based on region, North America emerged as the dominant region in the Global Companion Animal Pharmaceuticals Market in 2023, holding the largest market share in terms of value. One of the primary factors fueling the growth of the companion animal pharmaceuticals market in North America is the increasing trend of pet ownership. North America, particularly the United States and Canada, has seen a significant rise in the number of households that have pets, including dogs, cats, and other companion animals. These pets have become cherished members of the family, leading owners to invest in their well-being and healthcare. With more pets in homes, there is a higher demand for pharmaceutical products such as vaccines, medications, and supplements to maintain the health and longevity of these beloved animals. This surge in pet ownership is creating a robust market for pharmaceutical companies specializing in companion animal health.

North American pet owners are becoming increasingly aware of the importance of preventive healthcare for their animals. This awareness has translated into greater willingness to spend on veterinary care and pharmaceutical products. Regular check-ups, vaccinations, and treatments for common health issues have become the norm, further driving the demand for companion animal pharmaceuticals. Veterinarians in North America play a pivotal role in educating pet owners about the benefits of preventive care. They recommend and prescribe pharmaceutical products that cater to specific health needs, making them essential stakeholders in the companion animal pharmaceuticals market. As the awareness of pet healthcare continues to grow, the market for such products in North America is set to expand even further.

Key Market Players

Zoetis Services LLC

Merck & Co., Inc.

Boehringer Ingelheim International GmbH

Elanco Animal Health Incorporated

Virbac Taiwan Co., Ltd.

Vetoquinol S.A.

Dechra Pharmaceuticals Limited

Chanelle Pharma

KyoritsuSeiyaku Corp

Report Scope:

In this report, the Global Companion Animal Pharmaceuticals Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Companion Animal Pharmaceuticals Market, By Indication:

    Infectious diseases Dermatologic diseases Pain Orthopedic diseases Behavioural diseases Other

Companion Animal Pharmaceuticals Market, By Animal:

    Dogs Cats Horses Other

Companion Animal Pharmaceuticals Market, By Distribution Channel:

    Veterinary hospitals and clinics Retail pharmacies Others

Companion Animal Pharmaceuticals Market, By Region:

    North America

United States

Canada

Mexico

    Europe

France

United Kingdom

Italy

Germany

Spain

    Asia Pacific

China

India

Japan

Australia

South Korea

    South America

Brazil

Argentina

Colombia

    Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Companion Animal Pharmaceuticals Market.

Available Customizations:

Global Companion Animal Pharmaceuticals Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Companion Animal Pharmaceuticals Market Outlook

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share & Forecast
    • 4.2.1. By Indication (Infectious Diseases, Dermatologic Diseases, Pain, Orthopedic Diseases, Behavioral Diseases, Other)
    • 4.2.2. By Animal (Dogs, Cats, Horses, Other)
    • 4.2.3. By Distribution Channel (Veterinary Hospitals and Clinics, Retail Pharmacies, Others)
    • 4.2.4. By Region
    • 4.2.5. By Company (2023)
  • 4.3. Market Map
    • 4.3.1. By Indication
    • 4.3.2. By Animal
    • 4.3.3. By Distribution Channel
    • 4.3.4. By Region

5. Asia Pacific Companion Animal Pharmaceuticals Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Indication
    • 5.2.2. By Animal
    • 5.2.3. By Distribution Channel
    • 5.2.4. By Country
  • 5.3. Asia Pacific: Country Analysis
    • 5.3.1. China Companion Animal Pharmaceuticals Market Outlook
      • 5.3.1.1. Market Size & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share & Forecast
        • 5.3.1.2.1. By Indication
        • 5.3.1.2.2. By Animal
        • 5.3.1.2.3. By Distribution Channel
    • 5.3.2. India Companion Animal Pharmaceuticals Market Outlook
      • 5.3.2.1. Market Size & Forecast
        • 5.3.2.1.1. By Value
      • 5.3.2.2. Market Share & Forecast
        • 5.3.2.2.1. By Indication
        • 5.3.2.2.2. By Animal
        • 5.3.2.2.3. By Distribution Channel
    • 5.3.3. Australia Companion Animal Pharmaceuticals Market Outlook
      • 5.3.3.1. Market Size & Forecast
        • 5.3.3.1.1. By Value
      • 5.3.3.2. Market Share & Forecast
        • 5.3.3.2.1. By Indication
        • 5.3.3.2.2. By Animal
        • 5.3.3.2.3. By Distribution Channel
    • 5.3.4. Japan Companion Animal Pharmaceuticals Market Outlook
      • 5.3.4.1. Market Size & Forecast
        • 5.3.4.1.1. By Value
      • 5.3.4.2. Market Share & Forecast
        • 5.3.4.2.1. By Indication
        • 5.3.4.2.2. By Animal
        • 5.3.4.2.3. By Distribution Channel
    • 5.3.5. South Korea Companion Animal Pharmaceuticals Market Outlook
      • 5.3.5.1. Market Size & Forecast
        • 5.3.5.1.1. By Value
      • 5.3.5.2. Market Share & Forecast
        • 5.3.5.2.1. By Indication
        • 5.3.5.2.2. By Animal
        • 5.3.5.2.3. By Distribution Channel

6. Europe Companion Animal Pharmaceuticals Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Indication
    • 6.2.2. By Animal
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. Europe: Country Analysis
    • 6.3.1. France Companion Animal Pharmaceuticals Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Indication
        • 6.3.1.2.2. By Animal
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Germany Companion Animal Pharmaceuticals Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Indication
        • 6.3.2.2.2. By Animal
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Spain Companion Animal Pharmaceuticals Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Indication
        • 6.3.3.2.2. By Animal
        • 6.3.3.2.3. By Distribution Channel
    • 6.3.4. Italy Companion Animal Pharmaceuticals Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Indication
        • 6.3.4.2.2. By Animal
        • 6.3.4.2.3. By Distribution Channel
    • 6.3.5. United Kingdom Companion Animal Pharmaceuticals Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Indication
        • 6.3.5.2.2. By Animal
        • 6.3.5.2.3. By Distribution Channel

7. North America Companion Animal Pharmaceuticals Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Indication
    • 7.2.2. By Animal
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Companion Animal Pharmaceuticals Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Indication
        • 7.3.1.2.2. By Animal
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. Mexico Companion Animal Pharmaceuticals Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Indication
        • 7.3.2.2.2. By Animal
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. Canada Companion Animal Pharmaceuticals Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Indication
        • 7.3.3.2.2. By Animal
        • 7.3.3.2.3. By Distribution Channel

8. South America Companion Animal Pharmaceuticals Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Indication
    • 8.2.2. By Animal
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. South America: Country Analysis
    • 8.3.1. Brazil Companion Animal Pharmaceuticals Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Indication
        • 8.3.1.2.2. By Animal
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. Argentina Companion Animal Pharmaceuticals Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Indication
        • 8.3.2.2.2. By Animal
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Colombia Companion Animal Pharmaceuticals Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Indication
        • 8.3.3.2.2. By Animal
        • 8.3.3.2.3. By Distribution Channel

9. Middle East and Africa Companion Animal Pharmaceuticals Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Indication
    • 9.2.2. By Animal
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. MEA: Country Analysis
    • 9.3.1. South Africa Companion Animal Pharmaceuticals Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Indication
        • 9.3.1.2.2. By Animal
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. Saudi Arabia Companion Animal Pharmaceuticals Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Indication
        • 9.3.2.2.2. By Animal
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. UAE Companion Animal Pharmaceuticals Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Indication
        • 9.3.3.2.2. By Animal
        • 9.3.3.2.3. By Distribution Channel

10. Market Dynamics

  • 10.1. Drivers
  • 10.2. Challenges

11. Market Trends & Developments

  • 11.1. Recent Developments
  • 11.2. Product Launches
  • 11.3. Mergers & Acquisitions

12. Global Companion Animal Pharmaceuticals Market: SWOT Analysis

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product

14. Competitive Landscape

  • 14.1. Zoetis Services LLC
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Product & Services
    • 14.1.4. Financials (In case of listed)
    • 14.1.5. Recent Developments
    • 14.1.6. SWOT Analysis
  • 14.2. Merck & Co., Inc.
  • 14.3. Boehringer Ingelheim International GmbH
  • 14.4. Elanco Animal Health Incorporated
  • 14.5. Virbac Taiwan Co., Ltd.
  • 14.6. Vetoquinol S.A.
  • 14.7. Dechra Pharmaceuticals Limited
  • 14.8. Chanelle Pharma
  • 14.9. KyoritsuSeiyaku Corp

15. Strategic Recommendations

16. About Us & Disclaimer

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제